WuXi – Talk Bio

Key Presentations at JPM25: AbbVie, UCB, WuXi Biologics Highlight Industry Trends

3 months ago talkbio0Tagged AbbVie, Biological Factors, biotech, healthcare innovation, J.P. Morgan Healthcare, JPM25, trends qualifier, UCB, WuXi

JPM25, J.P. Morgan Healthcare Conference, AbbVie, UCB, WuXi Biologics, Biotech Trends, Healthcare Innovation

WuXi Biologics Divests Irish Vaccine Facility to Merck for $500 Million Amid Strategic Shift

4 months ago talkbio0Tagged asset, Biological Factors, BIOSECURE, Dundalk, Facility (object), Ireland, Merck, regulatory, Sales - occupational activity, strategic shift, Vaccines, WuXi

WuXi Biologics, Merck, vaccine manufacturing facility, Dundalk, Ireland, asset sale, strategic shift, regulatory changes, Biosecure Act

Merck Acquires WuXi Biologics’ Irish Vaccine Facility in $500M Deal

4 months ago talkbio0Tagged Biological Factors, Facility (object), Ireland, Merck, pharmaceutical manufacturing, Vaccines, WuXi

Merck, WuXi Biologics, vaccine facility, Ireland, $500M deal, pharmaceutical manufacturing

WuXi AppTec Divests Cell and Gene Therapy Units to Altaris in Strategic Shift

4 months ago talkbio0Tagged Altaris ', AppTec, Cells, gene therapy, Pharmaceutical Outsourcing, Strategic Divestment, WuXi

WuXi AppTec, Cell and Gene Therapy, Altaris, Strategic Divestment, Biosecure Act, Pharmaceutical Outsourcing

GSK Exits Biotechnology Innovation Organization (BIO) for 2025, Joining Takeda, UCB, and Others

5 months ago talkbio0Tagged AbbVie, AppTec, Bio, Biotechnology, Drug Industry, lobbying, Pfizer, SmithKline Beecham, Takeda, TNFRSF19 gene, UCB, WuXi

GSK, BIO, Biotechnology Innovation Organization, Takeda, UCB, Pfizer, WuXi AppTec, AbbVie, pharmaceutical industry, trade group, lobbying

WuXi AppTec Continues to Attract New Clients Amid BIOSECURE Act Uncertainty

6 months ago talkbio0Tagged AppTec, BIOSECURE, chain vulnerabilities, Chinese, Chinese contract manufacturer, Clients, Drug Industry, Senate consideration, WuXi

WuXi AppTec, BIOSECURE Act, new clients, revenue decline, Chinese contract manufacturer, U.S. Senate consideration, pharmaceutical industry, supply chain vulnerabilities.

WuXi AppTec Faces Uncertainty Amid BIOSECURE Act, Yet Continues to Secure New Projects

6 months ago talkbio0Tagged AppTec, Biopharma, BIOSECURE, CDMOs, Contract agreement, Industry, Legislation, manufacturing organizations, National Security Concerns, Outsourcing, United States, WuXi

BIOSECURE Act, WuXi AppTec, Biotechnology Industry, U.S. Legislation, Contract Development and Manufacturing Organizations (CDMOs), Biopharma Outsourcing, National Security Concerns